Natera Inc: president Moshkevich sells $479k in stock

Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), a $22.2 billion market cap company whose stock has gained over 23% in the past year, sold 2,999 shares of common stock on October 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed under a pre-arranged 10b5-1 trading plan, fetched a total of $479968.

The transactions involved three separate sales. The prices obtained for these sales ranged from $158.9606 to $160.7008 per share.

Following these transactions, Moshkevich directly owns 117,559 shares of Natera, Inc. The company maintains a GOOD financial health score according to InvestingPro’s comprehensive analysis, which offers detailed insights through its Pro Research Report, available among 1,400+ top US stocks.

In other recent news, Natera, Inc. has made significant strides in its clinical trials and research efforts. The company has enrolled over 1,600 patients in its EXPAND trial, which is evaluating the Fetal Focus single gene noninvasive prenatal test. This trial aims to confirm test results through diagnostic testing and includes a diverse, multi-ethnic population. Additionally, Natera announced that its Signatera test outperformed standard markers in a study of testicular cancer, analyzing 324 plasma samples from 74 patients. This was further supported by strong results from another study validating Signatera for monitoring uterine cancer, involving 233 samples from 61 patients.

Furthermore, Wells Fargo resumed coverage of Natera with an Equal Weight rating, citing its strong position in the cell-free DNA testing market. Piper Sandler reiterated an Overweight rating, following positive results from the company’s IMvigor011 trial, which showed significant advancements in Minimal Residual Disease testing. These developments highlight Natera’s ongoing commitment to advancing medical testing and diagnostics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.